Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin.

Diabetes Metab Syndr Obes · 2019 · PMC6899064 · PMID 31819580

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Fewer patients in the dapagliflozin group experienced a myocardial infarction (4.6% in the dapagliflozin arm versus 5.1% in the placebo arm), nevertheless the between group difference did not reach statistical significance (HR 0.80; 95% CI 0.77 to 1.01).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.